The estimated Net Worth of Arnon Rosenthal is at least $39.6 Миллион dollars as of 3 September 2024. Arnon Rosenthal owns over 26,499 units of Alector stock worth over $11,322,214 and over the last 5 years he sold ALEC stock worth over $21,438,112. In addition, he makes $6,854,340 as Chief Executive Officer, Co-Founder и Director at Alector.
Sign up
Arnon Rosenthal ALEC stock SEC Form 4 insiders trading
Arnon has made over 13 trades of the Alector stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 26,499 units of ALEC stock worth $129,315 on 3 September 2024.
The largest trade he's ever made was selling 200,000 units of Alector stock on 8 November 2021 worth over $5,000,000. On average, Arnon trades about 49,782 units every 57 days since 2019. As of 3 September 2024 he still owns at least 1,948,746 units of Alector stock.
You can see the complete history of Arnon Rosenthal stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Arnon Rosenthal biography
DR. Arnon Rosenthal Ph.D. serves as Chief Executive Officer, Co-Founder, Director of the Company. Dr. Rosenthal co-founded Annexon Biosciences, Inc. and served as its acting Chief Executive Officer from August 2011 to December 2014 and served as a member of the board of directors, including as Chairman from August 2011 to February 2017. Dr. Rosenthal co-founded Rinat Neuroscience Corporation (acquired by Pfizer Inc. in August 2006), and served as President, Chief Scientific Officer and as a member of the board of directors from August 2001 to August 2006. From January 1985 to August 2001, Dr. Rosenthal served in various roles at Genentech, Inc., where he ultimately served as Staff Scientist and was appointed as a permanent member of Genentech’s Research Review Committee where his team discovered the target for the cancer drug Erivedge. Dr. Rosenthal conducted his post-doctoral fellowship at Genentech, Inc. He holds a Ph.D. in biology from the Hebrew University of Jerusalem.
What is the salary of Arnon Rosenthal?
As the Chief Executive Officer, Co-Founder и Director of Alector, the total compensation of Arnon Rosenthal at Alector is $6,854,340. There are no executives at Alector getting paid more.
How old is Arnon Rosenthal?
Arnon Rosenthal is 64, he's been the Chief Executive Officer, Co-Founder и Director of Alector since 2019. There are 3 older and 16 younger executives at Alector. The oldest executive at Alector, Inc. is Louis Lavigne, 72, who is the Lead Independent Director.
What's Arnon Rosenthal's mailing address?
Arnon's mailing address filed with the SEC is C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Alector
Over the last 5 years, insiders at Alector have traded over $148,873,269 worth of Alector stock and bought 20,000 units worth $500,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Advisors Llc Orbi Med Capit... и Terrance Mcguire. On average, Alector executives and independent directors trade stock every 17 days with the average trade being worth of $438,922. The most recent stock trade was executed by Marc Grasso on 3 September 2024, trading 7,297 units of ALEC stock currently worth $35,609.
What does Alector do?
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
What does Alector's logo look like?
Complete history of Arnon Rosenthal stock trades at Alector
Alector executives and stock owners
Alector executives and other stock owners filed with the SEC include:
-
Arnon Rosenthal,
Chief Executive Officer, Co-Founder, Director -
Robert Paul,
Chief Medical Officer -
Robert King,
Chief Development Officer -
Dr. Robert Paul M.D., Ph.D.,
Advisor -
Dr. Arnon Rosenthal,
Co-Founder, CEO & Director -
Dr. Robert S. King,
Chief Devel. Officer -
Kristine Yaffe,
Independent Director -
Calvin Yu,
VP of Fin. -
Louis Lavigne,
Lead Independent Director -
Tillman Gerngross,
Chairman of the Board, Co-Founder -
Richard Scheller,
Independent Director -
Terry McGuire,
Independent Director -
David Wehner,
Independent Director -
Dr. Tillman Ulf Gerngross Ph.D.,
Co-Founder & Chairman -
Paula Hammond,
Independent Director -
Sabah Oney,
Chief Business Officer -
Calvin Yu,
Vice President - Finance -
Shehnaaz Suliman,
President, Chief Operating Officer -
Michelle Corral,
VP of Communications & Investor Relations -
Linda M. Rubinstein,
Interim CFO, Principal Financial Officer & Principal Accounting Officer -
Dr. Sara Kenkare-Mitra Ph.D.,
Pres and Head of R&D -
Clare Hunt M.B.A.,
Head of People -
Erica Jefferson,
VP of Communications & Public Affairs -
Brian Sander J.D., Ph.D.,
Gen. Counsel -
Charles Wolfus,
VP of Technology & Digital Health -
Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A.,
Pres , COO & Interim Chief Bus. Officer -
Advisors Llc Orbi Med Capit...,
-
Advisors Llc Orbi Med Capit...,
-
Terrance Mcguire,
Director -
Elizabeth A. Garofalo,
-
Venture Management Co. Vi, ...,
-
Marc Grasso,
Chief Financial Officer -
Sara Kenkare Mitra,
President and Head of R&D -
Errol B Desouza,
-
Mark Altmeyer,
-
Gary Romano,
Chief Medical Officer